Blaize Holdings announced a collaboration with Starshine Computing Power Technology Limited to deploy its hybrid AI platform across Asia Pacific markets, in an agreement valued at a minimum of $120 million over an 18-month period.

Blaize shares soared 68% in premarket trading on Friday.

The deployment will begin in the third fiscal quarter of 2025 and continue through 2026, initially focusing on smart city applications across India, Indonesia, Japan, South Korea, and China, according to the company’s statement.

The partnership aims to integrate Blaize’s Graph Streaming Processor-based inference accelerators with existing GPU infrastructure to create hybrid AI computing clusters for applications in urban surveillance, retail operations, industrial automation, and agricultural resource management.

More details: Blaize Secures $120M Contract for Hybrid AI Infrastructure in Asia

Talen Energy is acquiring two power plants located in Pennsylvania and Ohio for a net $3.5 billion, it said on Thursday, adding that it expects the move to boost the company's free cash flow per share by over 40% in 2026.

Shares of the company jumped about 14% in premarket trading on Friday.

In June, Talen expanded its nuclear energy partnership with Amazon to supply up to 1,920 MW of electricity from its Susquehanna plant in Pennsylvania to cope up with the increasing electricity demand.

More details: Talen to Acquire Power Stations in Pennsylvania, Ohio for $3.5 Billion

BlackSky Technology stock plunged about 15% in premarket trading on Friday.

The comapny announced Thursday it has priced a $160 million offering of 8.25% Convertible Senior Notes due 2033, an increase from the previously announced $125 million. The company also granted initial purchasers an option to purchase up to an additional $25 million in notes.

The offering is expected to close on Monday, subject to customary closing conditions. The notes will be sold to qualified institutional buyers under Rule 144A of the Securities Act.

More details: BlackSky Stock Plunges After Announcing $160 Million Convertible Notes Offering

Sarepta Therapeutics said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths of two teenage boys.

Shares of Sarepta fell about 17% in premarket trading on Friday.

A company spokesperson said a patient had died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy, which often weakens muscles around the hips and shoulders. The company told regulators and investigators about the death “in an appropriate and timely manner,” the spokesperson said in a statement.

More details: Sarepta Says Another Patient Has Died After Gene Therapy